Silo Pharma Partners with Kymanox to Develop Ketamine Implant for Chronic Pain

Silo Pharma Teams Up with Kymanox to Develop Innovative Ketamine Implant for Chronic Pain

Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company dedicated to developing cutting-edge therapies, has partnered with Kymanox to design a specialised subcutaneous insertion device for SP-26, its ketamine-loaded implant aimed at treating fibromyalgia and chronic pain. The collaboration will focus on creating a proof-of-concept model, followed by building a full prototype and testing its feasibility to ensure the implant is delivered at the ideal depth in tissue for maximum efficacy and safety.

Eric Weisblum, CEO of Silo Pharma, expressed excitement about this crucial step forward. “Our earlier tests confirmed that we’ve developed the optimal formulation for the SP-26 implant. Now, we’re moving ahead with developing the insertion device that will be key for preclinical trials,” Weisblum shared. If all goes according to plan, SP-26 could become the first FDA-approved, at-home injectable ketamine-based therapy, providing long-lasting relief for patients with chronic pain—many of whom have limited options for sustained treatment.

This isn’t the first collaboration between Silo Pharma and Kymanox. The two companies are also working together on SPC-15, a potential treatment for stress-induced disorders like PTSD. Their ongoing partnership highlights Silo Pharma’s commitment to addressing some of the most pressing challenges in healthcare by developing novel therapies that prioritize both safety and patient convenience.